TV Presenter & Finance EditorTV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Velo3D (NASDAQ:VELO) has secured an Other Transaction Agreement worth $32.6 million with the U.S. Department of War's Defense Innovation Unit to support Project FORGE, aimed at eliminating production bottlenecks for a major weapon system program.
Netflix (NASDAQ:NFLX) has secured up to $25 billion in bank financing to fund its proposed $72 billion acquisition of Warner Bros. Discovery’s movie studio and HBO Max streaming business.
Vertical Aerospace (NYSE:EVTL), the British developer of electric vertical take-off and landing (eVTOL) aircraft, has reached a critical milestone in its path toward commercial flight.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal step in moving the blockbuster treatment into earlier, potentially curative stages of breast cancer.
Telix Pharmaceuticals (NASDAQ:TLX) moved closer to expanding its global footprint in precision medicine on Sunday, reporting successful Phase 3 results for its flagship prostate cancer imaging agent in China and clearing regulatory hurdles for its broader pipeline in the United States.
Michael Saylor is signalling another Bitcoin purchase even as Strategy’s share price continues to slide, testing investor confidence in his long-term strategy.
US senators have confirmed a January 2026 markup for the CLARITY Act, signalling momentum toward long-awaited crypto market structure reform.
Brazil’s crypto market recorded a 43% surge in transaction volume in 2025, as investors committed more capital per account, diversified their holdings, and increasingly treated digital assets as part of long-term portfolio strategies rather than short-term speculation.
Mayne Pharma Group (ASX:MYX) reported total net revenues of $165 million, a 5.5% decrease compared to the prior corresponding period.
Evaxion (NASDAQ:EVAX) announced today that MSD has opted not to exercise its option to develop the protein-based version of Evaxion’s Gonorrhea vaccine candidate, EVX-B2.
